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Because the prevalence of obesity has increased dramatically in recent years, one of the key targets of public 
health is obesity and its associated pathological conditions. Obesity occurs as a result of white adipose tissue 
enlargement, caused by adipocyte hyperplasia and/or hypertrophy. Recently, endocrine aspects of adipose tis-
sue have become an active research area and these adipose tissue-derived factors are referred to as adipokines. 
These adipokines interact with a range of processes in many different organ systems and influence a various 
systemic phenomena. Therefore, dysregulated production of adipokines has been found to participate in the 
development of metabolic and vascular diseases related to obesity. The obese state is also known to be associated 
with increased local and systemic inflammation. Adipokines influence not only systemic insulin resistance and 
have pathophysiological roles in the metabolic syndrome and cardiovascular disease, but also contribute toward 
an increase in local and systemic inflammation. Thus, circulating levels of adipokines can be used as 
high-throughput biomarkers to assess the obesity-related health problems, including low grade inflammation. 
This review focuses on the usefulness of measuring circulating adipokine levels for the assessment of obe-
sity-related health problems. 
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1. Introduction 
The prevalence of obesity has increased dra-
matically as a result of our modern lifestyle and is one 
of the most important targets of public health pro-
grams [1]. Accumulating evidence derived from both 
clinical and experimental studies highlight the asso-
ciation of obesity with a number of chronic diseases 
such as type II diabetes mellitus (T2DM), atheroscle-
rosis and cardiovascular disease (CVD). T2DM is a 
problem not only in developed countries but is also 
becoming an urgent problem in developing countries 
owing to the worldwide increase in obesity [2]. 
Therefore, there is considerable effort to understand 
the underlying biology of these disease states and to 
identify the contributing risk factors. 
The clustering of CVD risk factors, most notably 
the simultaneous presence of obesity, T2DM, dyslipi-
demia, and hypertension was recognized as an im-
portant pathophysiological state [3-5]. The coexistence 
of these diseases has been termed the metabolic syn-
drome (MS). Insulin resistance (IR) is well known to be 
a key feature of MS, and is strongly associated with 
excess adiposity, especially in the intra-abdominal 
region. Individuals with MS are at increased risk for 
the development of CVD and other diseases related to 
plaque formation in artery walls, resulting in stroke 
and peripheral vascular disease. Because the preva-
lence of these diseases is increasing, high throughput 
assessment of disease states accompanied with obesity 
or MS are important issues from the public health 
point of view.  
Excess white adipose tissue (WAT) is linked to 
obesity-related health problems. It is also recognized 
that obesity is accompanied by chronic, low-level in-
flammation of WAT [6, 7]. Inflammation has been 
considered to be associated with the development of 
IR and MS [8]. Recently, WAT has been recognized as 
an important endocrine organ that secretes a wide va-
riety of biologically active adipokines [9-11]. Since 
some of these adipokines greatly influence insulin 
sensitivity, glucose metabolism, inflammation and 
atherosclerosis, they may provide a molecular link 
between increased adiposity and the development of 
T2DM, MS and CVD. The signals from WAT are 
thought to directly connect with IR and inflammation. Int. J. Med. Sci. 2008, 5 
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It is expected, therefore, that circulating levels of adi-
pokines may be useful as biomarkers to evaluate the 
risk of other disease states associated with obesity.  
This review describes the usefulness and clinical 
significance of circulating adipokine levels. First, I fo-
cused on three representative adipokines associated 
with IR, namely adiponectin, retinol binding protein 4 
(RBP4) and resistin. Next, I discuss the inflamma-
tion-related markers such as tumor necrosis factor 
(TNF)  α, interleukin (IL)-6 and C-reactive protein 
(CRP). Because leptin has not been recognized directly 
to be related with IR and inflammation, description of 
this adipokine was excluded. Finally, I have summa-
rized the significance of other molecules, followed by a 




2. Adipose tissue as a secretory organ 
 
In 1993, it was discovered that TNFα expression 
was up-regulated in WAT of obese mice [12]. The role 
of WAT as a hormone-producing organ became well 
recognized in 1994 with the discovery of leptin as an 
adipocyte-secreted protein [13]. Systemic analysis of 
the active genes in WAT, by constructing a 3’-directed 
complementary DNA library, revealed a high fre-
quency of genes encoding secretory proteins. Of the 
gene group classified by function, approximately 
20–30% of all genes in WAT encode secretory proteins 
[14].  
In adults, most organ systems have reached their 
final size and are programmed to be maintained at 
steady state. However, WAT is unique because of its 
almost unlimited expansion potential. Thus, WAT can 
become one of the largest organs in the body, and the 
total amount of an adipokine secreted from WAT may 
affect whole-body homeostasis. WAT contains various 
types of cells that include preadipocytes, adipocytes 
and stromal vascular cells. Moreover, bone mar-
row-derived macrophages home to WAT in obesity [6, 
7]. The massive increase in fat mass leads to a dys-
regulation of circulating adipokine levels that may 
have pathogenic effects associated with obesity. Thus, 
dysregulated secretion of adipokines, not only from 
adipocytes but also from macrophages in WAT, will 
contribute to the pathogenesis of obesity by triggering 
IR and systemic inflammation (Fig. 1). It is expected, 
therefore, that circulating levels of adipokines can be 
used as a high-throughput biomarker to assess obe-
sity-related health problems.  
 
Figure 1. Schematic representation of mechanisms linking 
adipokine dysreguation and cardiovascular disease in obese 
state. See text for abbreviations. 
3. Adiponectin 
Adiponectin is the most abundantly expressed 
adipokine in WAT [14]. The average levels of adi-
ponectin in human plasma are 5–10 μg/ml [15]. Adi-
ponectin is a multifunctional protein that exerts plei-
otropic insulin-sensitizing effects. It lowers hepatic 
glucose production [16] and increases glucose uptake 
and fatty acid oxidation in skeletal muscle [17]. 
Moreover, adiponectin may possess anti-atherogenic 
properties by inhibiting the expression of adhesion 
molecules and smooth muscle cell proliferation, as 
well as suppressing the conversion of macrophages to 
foam cells [18, 19]. An anti-inflammatory role of adi-
ponectin has also been reported [20]. 
A number of studies reported the significance of 
circulating levels of adiponectin (Table 1). Unlike most 
adipokines, adiponectin mRNA in WAT and serum 
levels are decreased in obesity [21]. Adiponectin is the 
only adipokine that is known to be down-regulated in 
obesity. Plasma concentrations are negatively corre-
lated with body mass index (BMI) [15]. A longitudinal 
study in primates suggests that adiponectin decreases 
with weight gain as animals become obese [22]. In 
contrast, weight loss results in significant increases in 
circulating adiponectin levels [23, 24]. In addition to 
the association with whole-body fat mass, adiponectin 
levels differ with the distribution of body fat. Plasma 
levels of adiponectin exhibit strong negative correla-
tions with intra-abdominal fat mass [25]. Visceral, but 
not subcutaneous abdominal fat, was reported to be 
inversely associated with plasma adiponectin levels in 
healthy women [26]. A low waist to hip ratio has been 
reported to be associated with high levels of plasma 
adiponectin independent of the body fat percentage 
[27].  Int. J. Med. Sci. 2008, 5 
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Table 1 Clinical studies of circulating adiponectin levels 
Subjects Major  findings  References   
Obese subjects   Decreased in obese subjects  Hu et al., (1996) [21]  
   Arita et al., (1999) [15] 
Patients with CVD  Decreased in patients with CVD  Ouchi et al., (1999) [37] 
Nondiabetic and T2DM subjects  Decreased in T2DM patients  Hotta et al., (2000) [28] 
Obese subjects  Increased after weight loss  Yang et al., (2001) [23] 
Caucasians and Pima Indians  Associated with IR  Weyer et al., (2001) [153] 
Pima Indian  Low plasma concentration precedes a decrease in insulin sensitivity  Stefan et al., (2002) [29] 
Pima Indian  Decreased in T2DM patients  Lindsay et al., (2002) [30]  
Pima Indian children  An inverse relationship to adiposity  Stefan et al., (2002) [154] 
Nondiabetic Japanese women  Negative correlation with serum triglyceride  Matsubara et al., (2002) [155] 
Obese subjects  Increased after weight loss  Bruun et al., (2003) [24] 
Middle-aged population  Associated with intra-abdominal fat  Cnop et al., (2003) [25] 
Nondiabetic white volunteers  Positive correlation with HDL-cholesterol  Tschritter et al., (2003) [31] 
Hypertensive patients  Correlation with vasodilator response  Ouchi et al., (2003) [34]  
Japanese men  Decreased in patients with CVD  Kumada et al., (2003) [38] 
Japanese subjects  Connected with endothelial dysfunction  Shimabukuro et al., (2003) [156]
Japanese subjects  Decreased in patients with T2DM  Daimon et al., (2003) [157] 
Apparently healthy individuals  Associated with the risk of T2DM  Spranger et al., (2003) [158] 
Asian Indians with IGT  Low adiponectin was a strong predictor of T2DM  Snehalatha et al., (2003) [159] 
Nonobese and obese subjects  Correlation with advantageous lipid profile  Baratta et al., (2004) [32] 
Japanese men  Decreased in hypertensive men  Iwashima et al., (2004) [33] 
Male participants  High adiponectin was associated with lower risk of myocardial infarction Pischon et al., (2004) [39] 
Whites and African Americans  Higher adiponectin was associated with a lower incidence of T2DM  Duncan et al., (2004) [160] 
Patients with CVD  Decreased in patients with CVD  Nakamura et al., (2004) [161] 
Pregnant women  Decreased in patients with gestational DM  Ranheim et al., (2004) [162] 
Nondiabetic subjects  Obesity-independent association of IR with adiponectin levels  Abbasi et al., (2004) [163] 
Obese individuals  Decreased in subjects with MS  Xydakis et al., (2004) [164] 
Healthy premenopausal women  Associated with visceral fat mass  Kwon et al., (2005) [26] 
Obese juveniles  An inverse relation with the intima media thickness of common carotid 
arteries 
Pilz et al., (2005) [40] 
Patients with chronic heart failure High adiponectin was a predictor of mortality  Kistorp et al., (2005) [42] 
British women  No association with CVD risk  Lawlor et al., (2005) [43] 
American Indian  No association with later development of CVD  Lindsay et al., (2005) [44] 
Hispanic children  Inversely associated with IR  Butte et al., (2005) [52] 
Patients with CVD  Decreased in patients with CVD  Rothenbacher et al., (2005) [165]
Middle-aged men  Positive association with lower fat mass  Buemann et al., (2005) [166] 
Obese children  Low adiponectin was associated with components of MS  Winer et al., (2006) [36] 
Older Black Americans  High adiponectin was associated with higher risk of CVD  Kanaya et al., (2006) [45] 
Patients with CVD  High adiponectin was a predictor of mortality  Cavusoglu et al., (2006) [46] 
Patients with CVD  High adiponectin was a predictor of mortality  Pilz et al., (2006) [50] 
Pregnant women  Elevated with preeclampsia  Haugen et al., (2006) [59] 
Patients with congestive heart 
failure 
Positive correlation with disease severity  George et al., (2006) [167] 
Caucasian  High adiponectin increased the risk of death from all causes  Laughlin et al., (2007) [48] 
Aged men  High adiponectin increased the risk of death from all causes  Wannamethee et al., (2007) [49]
Patients with incident CVD    No association with the prognostic outcome  von Eynatten et al., (2008) [41] 
General Dutch population  High levels of adiponectin predict mortality  Dekker et al., (2008) [51] 
 
Plasma adiponectin concentrations are lower in 
people with T2DM than in BMI-matched controls [28]. 
The plasma concentrations have been shown to corre-
late strongly with insulin sensitivity, which suggests 
that low plasma concentrations are associated with IR 
[29]. In a study of Pima Indians, a population that has 
one of the highest prevalence of obesity, IR and T2DM, 
individuals with high adiponectin levels were less 
likely to develop T2DM than those with low concen-
trations [30]. The high adiponectin concentration was, 
therefore, a predictive marker for the development of 
T2DM. Plasma concentrations of adiponectin are also 
r e p o r t e d  t o  b e  a s s o c i a t e d  w i t h  c o m p o n e n t s  o f  M S .  
High plasma concentrations of adiponectin were 
found to be related to an advantageous blood lipid 
profile [31, 32]. Plasma adiponectin levels are de-
creased in hypertensive humans, irrespective of the 
presence of IR [33]. Endothelium-dependent vasoreac-
tivity is impaired in people with hypoadiponectinemia 
[34], which might be one of the mechanisms involved 
in hypertension in visceral obesity. A reciprocal asso-
ciation between CRP and adiponectin mRNA levels 
w a s  r e p o r t e d  i n  h u m a n  W A T ,  s u g g e s t i n g  t h a t  h y -
poadiponectinemia appears to contribute to low-grade Int. J. Med. Sci. 2008, 5 
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systemic chronic inflammation [35]. All these mecha-
nisms may underlie the protective effects against the 
progression of atherosclerosis of adiponectin. A recent 
study revealed that adiponectin may function as a 
biomarker for MS, even in childhood obesity [36]. 
Collectively, adiponectin has been recognized as a key 
molecule in MS and has the potential to become a 
clinically relevant parameter to be measured routinely 
at general medical check ups.  
Plasma concentrations of adiponectin are also 
known to be lower in people with CVD than in con-
trols, even after matching for BMI and age [37]. A 
case-control study performed in Japan revealed that 
the people with hypoadiponectinemia with the plasma 
levels less than 4 μg/ml had increased risk of CVD and 
multiple metabolic risk factors, indicating that hy-
poadiponectinemia is a key factor in MS [38]. Retro-
spective case-control studies have demonstrated that 
patients with the highest levels of adiponectin have a 
dramatically reduced 6-year risk of myocardial infarc-
tion compared with case controls with the lowest adi-
ponectin levels, and this relationship persists even 
after controlling for family history, BMI, alcohol, his-
tory of diabetes and hypertension, hemoglobin A1c, 
CRP, and lipoprotein levels [39]. An inverse relation-
ship between serum adiponectin levels and the intima 
media thickness of common carotid arteries was also 
reported [40]. These clinical studies clearly indicate 
that hypoadiponectinemia is a strong risk factor for 
CVD.  
Although the above studies support the notion 
that adiponectin would protect against vascular dis-
eases, recent epidemiological studies have failed to 
support this notion [41-51]. A recent prospective study 
reported adiponectin levels were not significantly as-
sociated with future secondary CVD events [41]. Thus, 
measurement of adiponectin may add no significant 
value to risk stratifications in patients with incident 
CVD, and effects of adiponectin may be more of im-
portance in the early phases of atherosclerosis. Kistorp 
et al. reported that adiponectin was positively related 
to increased mortality in patients with chronic heart 
failure [42]. These authors suspect that the high adi-
ponectin concentrations may reflect a wasting process 
in subjects with increased risk of death. Pilz et al. re-
ported that high adiponectin levels predict all-cause, 
cardiovascular and noncardiovascular mortality [50]. 
A recent study also reported that a high adiponectin 
level was a significant predictor of all-cause and CVD 
mortality [51]. These authors hypothesized that a 
counter-regulatory increase in adiponectin occurs, 
which represents a defense mechanism of the body 
against cardiovascular alterations and a 
pro-inflammatory state associated with CVD. Thus, 
yet-unknown mechanisms may underlie the associa-
tion between adiponectin and the risk of death, the 
prognostic value of adiponectin remains unresolved. 
Further prospective studies will be required to provide 
conclusive results about the association of adiponectin 
and mortality. It is also necessary to understand the 
underlying molecular mechanisms of elevated adi-
ponectin concentrations in these disease states.  
It must be highlighted that several physiological 
factors affect the circulating levels of adiponectin. First, 
aging, gender and puberty have effects on circulating 
adiponectin levels [52, 53]. An age-associated elevation 
of plasma adiponectin levels has been reported [51, 
54]. Plasma adiponectin levels were significantly 
higher in female subjects, indicative of a sex hormone 
affect on circulating adiponectin levels [51, 55]. Adi-
ponectin levels tend to decrease throughout puberty, 
which parallels the development of IR [36, 56]. Second, 
the glomerular filtration rate has been recognized as a 
strong inverse predictor of adiponectin. The clearance 
of adiponectin by the kidney may have a strong in-
fluence on its concentration [57]. Hence, high adi-
ponectin levels may reflect impaired renal function. 
Last but not least, an increased adiponectin level has 
been suggested to act as a compensatory mechanism to 
dampen inflammation. Indeed, elevated plasma adi-
ponectin concentrations are observed in several dis-
eases associated with inflammation: arthritis [58], 
preeclampsia [59], and end-stage renal disease [60]. All 
of these factors must be considered when evaluating 
the clinical significance of circulating adiponectin lev-
els in MS or vascular diseases related to obesity.  
Circulating adiponectin forms several different 
complexes in the adipocyte before being secreted into 
the blood [61]. Commercial assays measure the total 
plasma concentration of adiponectin. Thus, the vast 
majority of clinical studies published to date have 
evaluated correlations between total adiponectin levels 
and various markers of MS. The most basic form of 
adiponectin secreted is the trimer. Adiponectin forms 
two higher-ordered structures through the noncova-
lent binding of two trimers (hexamers) and six trimers 
(18mers). The native protein circulates in serum as low 
molecular weight (LMW) hexamers and as larger mul-
timeric structures of high molecular weight (HMW). 
Of these higher-ordered structures, the 18mer (HMW) 
form is assumed to act beneficial against IR; the func-
tion of the hexamer (LMW) form is suggested to play a 
pro-inflammatory role [55, 62]. Thus, the HMW form is 
more strongly associated with insulin sensitivity than 
is total adiponectin [63-65]. Overall, these results sug-
gest that the assessment of total adiponectin may be 
insufficient and that the analysis of the levels of the Int. J. Med. Sci. 2008, 5 
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multimeric forms should be favorable to assess the 
significance of adiponectin.  
4. Retinol binding protein 4 (RBP4) 
RBP4 is a protein that is the specific carrier for 
retinol in the blood. It is one of a large number of pro-
teins that solubilize and stabilize the hydrophobic and 
labile metabolites of retinoids in aqueous spaces in 
both extra- and intracellular spaces. Its physiological 
function appears to be to bind retinol and prevent its 
loss through the kidneys. RBP4, although largely 
produced in liver, is also made by adipocytes, with 
increased levels in obesity contributing to impaired 
insulin action [66]. Studies in transgenic rodent models 
showed overexpression of human RBP4 or injection of 
recombinant RBP4 induced IR in mice, whereas RBP4 
knockout mice showed enhanced insulin sensitivity 
[66]. The same authors reported that high plasma RBP4 
l e v e l s  a r e  a s s o c i a t e d  w i t h  I R  s t a t e s  i n  h u m a n s  a n d  
suggested that RBP4 is an adipokine responsible for 
obesity-induced IR and, thus, a potential therapeutic 
target in T2DM [66, 67]. Since then, a number of clini-
cal studies have been conducted to assess the signifi-
cance of circulating levels of RBP4 (Table 2).  
Table 2 Clinical studies of circulating RBP4 levels 
Subjects Major  findings  References   
Obese and T2DM subjects  Elevated in subjects with T2DM  Yang et al., (2005) [66] 
IGT and T2DM subjects  Correlation with the magnitude of IR  Graham et al., (2006) [67]  
IGT and T2DM subjects  Elevated in subjects with IGT or T2DM than normal glucose tolerance  Cho et al., (2006) [68] 
Caucasian menopausal women  No correlation with adiposity  Janke et al., (2006) [72] 
Japanese subjects  No correlation with BMI  Takashima et al., (2006) [168] 
IGT and T2DM subjects  No correlation with IR  Erikstrup et al., (2006) [169] 
Chinese subjects  Correlation with the components of MS  Qi et al., (2007) [69] 
Healthy women  Associated with visceral fat  Lee et al., (2007) [70] 
Chinese subjects  Correlation with visceral adiposity  Jia et al., (2007) [71] 
Non diabetic person  No correlation with IR  Yao-Borengasser et al., (2007) 
[73] 
Subjects with BMI from 18 to 30  Negative correlation with insulin sensitivity  Gavi et al., (2007) [74] 
Caucasian without T2DM  Associated with liver fat  Stefan et al., (2007) [76] 
Nondiabetic individuals  Reflected ectopic fat accumulation  Perseghin et al., (2007) [77] 
Obese children  Associated positively with CRP  Balagopal et al., (2007) [170] 
Subjects with morbid obesity  Reduction after weight loss  Haider et al., (2007) [171] 
Obese women  Reduction after weight loss  Vitkova et al., (2007) [172] 
Patients with T2DM  Associated with IR  Takebayashi et al., (2007) [173] 
Women with polycystic ovary 
syndrome 
Elevated than BMI-matched subjects  Tan et al., (2007) [174] 
Nondiabetic men  Negatively associated with insulin secretion  Broch et al., (2007) [175] 
Patients with chronic liver dis-
ease 
Decreased compared with control subjects  Yagmur et al., (2007) [176] 
Patients with T2DM or CVD  Associated with pro-atherogenic lipoprotein levels  von Eynatten et al., (2007) [177] 
 
Cho et al. reported that plasma concentrations of 
RBP4 were higher in people with impaired glucose 
tolerance (IGT) or T2DM than in people with normal 
glucose tolerance [68]. A recent cross-sectional study of 
3289 middle-aged population showed that plasma 
RBP4 levels increased gradually with increasing 
numbers of MS components [69]. Similar to other adi-
pokines, circulating levels of RBP4 is associated with 
body fat distribution rather than body weight per se. 
RBP4 was reported to be more highly correlated with 
waist-to-hip ratio or visceral fat areas than with BMI 
[67, 70, 71]. However, Janke et al. reported that, in 
human abdominal subcutaneous (sc) adipose tissue, 
RBP4 mRNA is down-regulated in obese women, 
whereas circulating RBP4 concentrations were similar 
in lean, overweight, and obese women [72]. 
Yao-Borengasser et al. also reported that neither sc 
adipose tissue RBP4 mRNA expression nor circulating 
RBP4 levels show any correlation with BMI [73]. It is 
not clear why such differences are present among 
similarly conducted human studies. These inconsis-
tencies most likely result from differences in age, eth-
nicity, sample size, and assay methods used. For ex-
ample, sex and age were found to be independent de-
terminants of plasma RBP4 concentrations [68, 74]. A 
recent study suggested that the sandwich ELISA kit 
commercially available for the assessment of RBP4 
may overestimate the circulating levels [75]. Those 
authors also claimed that competitive EIAs may un-
derestimate serum RBP4 levels in the setting of IR 
owing to assay saturation. Thus, it is probable that the 
reported RBP4 associations would become clearer if 
more reliable assays were employed. 
Two recent studies have indicated that high cir-
culating RBP4 is associated with elevated liver fat and, 
presumably, hepatic insulin resistance [76, 77]. In ro-Int. J. Med. Sci. 2008, 5 
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dents, only 20% of systemic RBP4 is produced by adi-
pocytes, and RBP4 gene expression in adipocytes was 
20% compared with expression in the liver [78]. Thus, 
it is possible that the increase in systemic RBP4 con-
centrations is not explained by increased RBP4 pro-
duction in WAT. RBP4 is a transporter for retinol, 
which serves as a precursor for the synthesis of ligands 
for nuclear hormone receptors such as retinoid X re-
ceptor and retinoic acid receptor. Thus, circulating 
RBP4 can modulate metabolic pathways via these nu-
clear hormone receptors. Certainly, future prospective 
studies are needed to clarify whether a high RBP4 level 
plays a causal role in the development of MS, T2DM, 
and eventually for the development of CVD. 
5. Resistin 
After the identification of resistin as an adipokine 
in 2001 [79], several studies have been conducted to 
investigate the role and significance of this molecule. 
Resistin was discovered as a result of a hypothesis that 
WAT secretes a hormone that mediates IR and that 
insulin sensitizing drug thiazolidinediones act by 
suppressing the production of this hormone. Resistin 
is secreted by mature adipocytes in proportion to the 
level of obesity and acts on insulin-sensitive cells to 
antagonize insulin-mediated glucose uptake and 
utilization in mice. Treatment of wild-type mice with 
recombinant resistin resulted in IR, whereas admini-
stration of an anti-resistin antibody increased insulin 
sensitivity in obese and insulin-resistant animals [79]. 
However, human resistin is 59% homologous at the 
amino acid level to the mouse molecule, a relatively 
low degree of sequence conservation. Moreover, in 
contrast to mice, human resistin is expressed at lower 
levels in adipocytes but at higher levels in circulating 
blood monocytes [80]. As a result, there is still uncer-
tainty about possible relationships between serum 
concentrations of resistin and markers of IR (Table 3).  
Table 3 Clinical studies of circulating resistin levels 
Subjects Major  findings  References   
Healthy Greek students  Correlation with body fat mass  Yannakoulia et al., (2003) [81] 
Non-diabetic subjects   Correlation with IR  Silha et al., (2003) [82] 
Patients with essential hypertension  Elevated in T2DM patients  Zhang et al., (2003) [83] 
Patients with inflammatory diseases  Correlation with inflammatory markers  Stejskal et al., (2003) [91] 
Obese subjects  Correlation with BMI  Azuma et al., (2003) [178] 
Lean and obese subjects   Increase in obese subjects  Degawa-Yamauchi et al., 
(2003) [179] 
Women  No relation with fat mass or IR  Lee et al., (2003) [180] 
Patients with T2DM  No correlation with IR  Pfutzner et al., (2003) [181] 
Obese subjects  Not changed after weight loss  Monzillo et al., (2003) [182] 
Diabetic subjects   Correlation with CRP  Shetty et al., (2004) [87] 
Obese Caucasian subjects  Correlation with HOMA-R  Silha et al., (2004) [183] 
Non obese subjects  Correlation with insulin sensitivity  Heilbronn et al., (2004) [184] 
Pima Indians  Correlation with fat mass but not IR  Vozarova de Courten et al., 
(2004) [185]  
Diabetic subjects  Elevated in T2DM patients  Youn et al., (2004) [186]  
Japanese subjects   Elevated in T2DM patients  Fujinami et al., (2004) [187] 
Patients with T2DM  Correlation with hepatic fat content  Bajaj et al., (2004) [188] 
Women   Associated with the presence of CVD  Pischon et al., (2005) [88]  
Subjects who had a family history of premature 
coronary artery disease 
Correlation with the levels of inflammatory markers  Reilly et al., (2005) [90] 
Japanese subjects  Associated with the presence and severity of CVD  Ohmori et al., (2005) [189] 
Men  Correlation with CRP  Bo et al., (2005) [190] 
Patients with rheumatoid arthritis  Elevated than the patients with osteoarthritis  Senolt et al., (2007) [89] 
 
The role of resistin in the pathophysiology of 
obesity and IR in humans is controversial. Several 
studies have shown positive correlations of circulating 
resitin levels with body fat mass [80, 81] or IR [82, 83]. 
However, the other studies found no relationship be-
tween resistin gene expression and body weight or 
insulin sensitivity [84-86]. These conflicting data may 
reflect variations in the study design and the lack of 
adjustment for potential confounding factors. It also 
seems possible that resistin is a marker for, or contrib-
utes to, IR in a specific population. The predominantly 
paracrine role of resistin might explain the weakness of 
the correlations between circulating resistin levels and 
some of the metabolic variables.  
Two studies have shown that among the blood 
markers, the most significant association of the circu-
lating resistin level was with plasma CRP [87, 88]. 
Thus, higher resistin levels may be a marker of sys-
temic inflammation. Indeed, the circulating level of 
resistin is up-regulated in patients with rheumatoid 
arthritis [89]. The circulating resistin level is also re-
ported to be an inflammatory marker of atherosclerosis Int. J. Med. Sci. 2008, 5 
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[90]. Considering that the resistin concentration is 
elevated in the patients with severe inflammatory 
disease [91], hyperresistinemia may be a biomarker 
and/or a mediator of inflammatory states in humans. 
Overall, the resistin levels in humans are thought to 
correlate more closely with inflammation than with IR.   
6. Inflammation-related molecules 
Obesity is associated with a state of chronic, 
low-grade inflammation characterized by abnormal 
cytokine production and the activation of inflamma-
tory signaling pathways in WAT [92]. Obese hyper-
trophic adipocytes and stromal cells within WAT di-
rectly augment systemic inflammation. Although 
WAT is usually populated with 5-10% macrophages, 
diet-induced weight gain causes a significant macro-
phage infiltration, with macrophages comprising up to 
60% of all cells found in WAT in a rodent model [6]. 
Thus, several adipokines implicated in inflammation 
are cytokines which are produced by macrophages. 
The accumulation of WAT resident macrophages and 
elaboration of inflammatory cytokines have been im-
plicated in the development of obesity-related IR. In-
deed, increases in inflammatory cytokine expression 
by WAT are associated with a parallel increase in WAT 
macrophage content [6, 7, 93].  Thus, obesity leads to 
increased production of several inflammatory cyto-
kines, which play a critical role in obesity-related in-
flammation and metabolic pathologies.  
A number of studies have reported that several 
humoral markers of inflammation are elevated in 
people with obesity and T2DM [94, 95] (Table 4). 
Pfeiffer et al. showed that men with T2DM had higher 
TNFα concentrations compared with nondiabetic sub-
jects [96]. However, several studies reported no asso-
ciation between circulating levels of TNFα  and insulin 
sensitivity [97, 98]. Since there was no arteriovenous 
difference with TNFα [99], TNFα is considered to work 
mainly in an autocrine or paracrine manner, where the 
local concentrations would be more likely to exert its 
metabolic effects [99, 100]. Moreover, circulating TNFα 
has been reported to be associated with a soluble re-
ceptor that inhibits its biological activity [101], sug-
gesting that the action of TNFα is primarily a local one. 
Therefore, it seems unlikely that the circulating levels 
of TNFα would be a good biomarker to reflect the IR 
state of the whole body.  
 
Table 4 Clinical studies of circulating inflammatory markers 
Subjects Major  findings  References   
TNFα    
Nondiabetic offsprings of T2DM patients  Not major contributing factor for obesity induced IR  Kellerer et al., (1996) [97] 
Adult males  Elevated in patients with T2DM  Pfeiffer et al., (1997) [96] 
Obese patients with T2DM  Correlation with the visceral fat area  Katsuki et al., (1998) [191] 
T2DM subjects  Elevated in T2DM as compared to control  Winkler et al., (1998) [192]  
Aged men  Correlation with BMI  Nilsson et al., (1998) [193] 
Canadian population  Positive correlation with IR  Zinman et al., (1999) [194] 
Obese subjects  Elevated in obese subjects than in controls  Corica et al., (1999) [195] 
Normotensive obese patients  Elevated in patients with android obesity than gynoid obesity  Winkler et al., (1999) [196] 
Obese subjects  No relationship with BMI  Kern et al., (2001) [98] 
Premenopausal obese women  Reduced after weight loss  Ziccardi et al., (2002) [197] 
Nondiabetic obese women  Associated with fat amount  Maachi et al., (2004) [198] 
Premenopausal obese women  Reduced after weight loss  Marfella et al., (2004) [199] 
    
IL-6      
White nondiabetic subjects  Correlation with BMI  Yudkin et al., (1999) [100] 
Healthy middle-aged women  Associated with BMI  Hak et al., (1999) [200] 
Obese nondiabetic women  Reduced after weight loss  Bastard et al., (2000) [103] 
Obese subjects  Correlation with obesity and IR  Kern et al., (2001) [98] 
Pima Indians  Correlation with IR  Vozarova et al., (2001) [102] 
Premenopausal obese women  Reduced after weight loss  Ziccardi et al., (2002) [197] 
Premenopausal obese women  Reduced after weight loss  Esposito et al., (2003) [104] 
Obese patients  Reduced after weight loss  Kopp et al., (2003) [105] 
Obese subjects  Reduced after weight loss  Monzillo et al., (2003) [182] 
Premenopausal obese women  Reduced after weight loss  Giugliano et al., (2004) [106] 
Nondiabetic offspring of patients with 
T2DM 
Not associated with the components of MS  Salmenniemi et al., (2004) [110]
Premenopausal obese women  Reduced after weight loss  Marfella et al., (2004) [199]  
Japanese men  Not associated with the components of MS  Matsushita et al., (2006) [111] 
T2DM subjects  Associated with IR  Natali et al., (2006) [201] 
Adolescents  Positive correlation with BMI  Herder et al., (2007) [135]  
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CRP    
White nondiabetic subjects  Positive correlation with BMI  Yudkin et al., (1999) [100] 
Healthy middle-aged women  Associated with BMI  Hak et al., (1999) [200] 
Young adults  Elevated in obese person  Visser et al., (1999) [202] 
Adult men  Correlation with body fat mass  Lemieux et al., (2001) [115] 
Obese women  Reduced after weight loss  Heilbronn et al., (2001) [117] 
Middle-aged men  Predictor of T2DM development  Freeman et al., (2002) [116] 
Obese postmenopausal women  Reduced after weight loss  Tchernof et al., (2002) [118] 
Premenopausal obese women  Reduced after weight loss  Ziccardi et al., (2002) [197] 
Healthy obese women  Correlation with IR independent of obesity  McLaughlin et al., (2002) [203] 
Premenopausal obese women  Reduced after weight loss  Esposito et al., (2003) [104] 
Healthy American women  Prognostic marker to the MS  Ridker et al., (2003) [114] 
Premenopausal obese women  Obesity is the major determinant of elevated CRP levels  Escobar-Morreale et al., (2003) 
[204] 
Premenopausal obese women  Reduced after weight loss  Marfella et al., (2004) [199]  
Obese subjects  Correlation with serum TNFα levels  Shadid et al., (2006) [86] 
T2DM subjects  Associated with IR  Natali et al., (2006) [201] 
Overweight women  Reduced after weight loss  Moran et al., (2007) [205] 
 
A considerable proportion of circulating IL-6 is 
derived from WAT, and WAT is estimated to produce 
about 25% of the systemic IL-6 in vivo [99]. Fasting 
plasma IL-6 concentrations were negatively correlated 
with the rate of insulin-stimulated glucose disposal in 
Pima Indians [102]. Bastard et al. reported that the IL-6 
values were more strongly correlated with obesity and 
IR parameters than TNFα, and a very low-calorie diet 
induced significant decreases in circulating IL-6 levels 
in obese women [103]. Other studies have also showed 
that weight loss results in decreased circulating levels 
of IL-6 [104-106]. Although several reports have indi-
cated that IL-6 plays a role in the development of IR 
[95, 107], some investigators have insisted that IL-6 
prevents IR [108, 109]. Some of these discrepancies 
may be explained by the widely different characteris-
tics of the study populations regarding age, sex, glu-
cose tolerance status, and degree of obesity. Overall, 
the association of IL-6 and IR seems complex and IL-6 
alone might not be an appropriate marker of IR or MS 
[110, 111].   
IL-6 derived from visceral adipose tissue draining 
directly into the portal system and causes the obe-
sity-associated rise of liver CRP production [112]. Al-
though CRP was traditionally thought to be produced 
exclusively by the liver in response to inflammatory 
cytokines, emerging data indicate that CRP can also be 
produced by nonhepatic tissues. Adipocytes isolated 
from human WAT produced CRP in response to in-
flammatory cytokines [113]. Adiponectin has been 
suggested to play a role in modulating CRP levels. In 
fact, adiponectin knockout mice showed higher CRP 
mRNA levels in WAT compared with the wild-type 
mice [35]. Therefore, hypoadiponectinemia also ap-
pears to be responsible for a low-grade systemic 
chronic inflammatory state, which is closely related to 
high CRP levels.  
Several studies have shown that CRP is more 
strongly associated with IR than either TNFα or IL-6 
[110, 111, 114]. CRP has been reported to be associated 
with body fat and other inflammatory markers [86, 
115]. Abundant evidence has accumulated to show 
that CRP is associated with MS and predicts T2DM 
and CVD events independently of traditional risk fac-
tors [114, 116]. Thus, elevated CRP levels in obesity, 
and the decreases associated with weight loss indicate 
a link between CRP and obesity-associated risks for 
CVD [104, 117, 118].   
7. Chemokines: monocyte chemoattractant 
protein-1 and IL-8 
Monocyte chemoattractant protein-1 (MCP-1) is a 
chemokine, which plays a pivotal role in the recruit-
ment of monocytes and T lymphocytes to the sites of 
inflammation. MCP-1 is expressed in adipocytes and 
considered to be an adipokine [119, 120]. MCP-1 me-
diates the infiltration of macrophages into WAT in 
obesity and may play an important role in establishing 
and maintaining a proinflammatory state that predis-
poses to the development of IR and MS [121]. Macro-
phage infiltration into WAT is increased by the secre-
tion of MCP-1, which is expressed by adipocytes, as 
well as by macrophages and other cell types, especially 
in obese, insulin-resistant subjects [122]. A number of 
studies have reported significantly higher circulating 
MCP-1 levels in obese [122, 123] or T2DM patients 
[124, 125]. Conversely, obese patients who lost weight 
showed decreased levels of MCP-1 [122, 126]. How-
ever, a recent study indicated that there was no dif-
ference in circulating MCP-1 levels between nonobese 
and obese subjects, when either abdominal venous or 
arterialized blood was analyzed [127]. Previous studies 
showed that plasma MCP-1 levels were influenced by 
numerous factors, including aging [128], hypertension 
[129], hypercholesterolemia [130], vascular disease Int. J. Med. Sci. 2008, 5 
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[131], and renal failure [132]. Moreover, MCP-1 is also 
produced by other cell types, such as vascular smooth 
muscle cells, endothelial cells, fibroblasts, mesangial 
cells, and lymphocytes. Thus, undetectable conditions 
might have influenced the circulating MCP-1 levels, 
and it seems improbable that the circulating levels of 
MCP-1 merely reflect obesity-related disease states.  
IL-8 is responsible for the recruitment of neutro-
phils and T lymphocytes into the subendothelial space 
and considered to be an atherogenic factor that leads to 
intimal thickening. IL-8 is produced and secreted by 
human adipocytes [133]. Plasma IL-8 levels are in-
creased in obese subjects, linking obesity with in-
creased cardiovascular risk [134]. The circulating IL-8 
level is associated with obesity-related parameters 
such as BMI, waist circumference and CRP [123]. 
However, Herder et al. reported that, among the seven 
immunological mediators (IL-6, IL-18, TNFα, IL-8, 
MCP-1, IP-10, and adiponectin) expressed and secreted 
by WAT, high BMI was significantly associated with 
elevated circulating levels of IL-6, IL-18, and IP-10 as 
well as lower levels of adiponectin [135]. Thus, the 
clinical relevance of circulating levels of MCP-1 and 
IL-8 to predict obesity-related disease conditions is still 
unresolved.  
8. Other molecules 
Plasminogen activator inhibitor-1 (PAI-1) is an 
important endogenous inhibitor of tissue plasminogen 
activator and is a main determinant of fibrinolytic ac-
tivity. PAI-1 contributes to the pathogenesis of 
atherothrombosis and CVD. Experimental data indi-
cate that WAT has a capacity to produce PAI-1 [136]. 
Much of the elevation of circulating levels of PAI-1 in 
obesity is attributable to upregulated production from 
WAT [136-138]. The increased plasma PAI-1 levels in 
obesity and positive correlations with visceral fat de-
pots are reported in several studies [139-142]. Con-
versely, weight loss is associated with reduced PAI-1 
activity in obese subjects [143]. Hyperinsulinemia 
caused by IR may increase both adipocyte and hepatic 
synthesis of PAI, which could play a role in the de-
velopment of the vascular complications [144, 145]. 
Obesity is associated with expansion of the cap-
illary bed in regional fat depots. Adipocytes or other 
cell types present in WAT secrete angiogenic factors 
such as vascular endothelial growth factor (VEGF) and 
hepatocyte growth factor (HGF), which act in an 
autocrine or paracrine manner within WAT but may 
have endocrine effects throughout the body. Serum 
VEGF levels were found to positively correlate with 
BMI [146, 147]. HGF has also been reported to be ele-
vated in obese subjects [148] and elevated serum HGF 
in obese subjects is reduced with weight loss [149]. 
These angiogenic factors may be involved in the de-
velopment of obesity-related metabolic disorders such 
as inflammation and CVD.  
Cathepsin S was recently identified as a novel 
adipokine [150]. Cathepsin S is a cysteine protease that 
has the ability to degrade many extracellular elements 
and is involved in the pathogenesis of atherosclerosis 
[151]. Cathepsin S is secreted by adipocytes and its 
circulating levels are increased in obese subjects than 
in nonobese subjects [152]. Conversely, weight loss is 
associated with a decrease in circulating cathepsin S 
levels as well as WAT cathepsin S content [152]. Thus, 
cathepsin S could constitute a novel biomarker of 
adiposity that may be linked with enlarged WAT and 
may also play a role in vascular pathogenesis in obe-
sity. 
9. Conclusions 
Obesity is recognized as a worldwide public 
health problem that contributes to a wide range of 
disease conditions. The development of a method for 
convenient prediction of obesity-related health prob-
lems represents a major challenge for public policy 
makers facing the epidemic of obesity.  WAT is an 
endocrine organ that communicates with other tissues 
via secretion of adipokines. Adipokines, which inte-
grate metabolic and inflammatory signals are attrac-
tive candidates for predicting the risk of CVD. With 
obesity, the production of most adipokines is en-
hanced, except for the anti-inflammatory and insu-
lin-sensitizing effector, adiponectin. Enlarged adipo-
cytes and macrophages embedded within WAT pro-
duce more RBP4, resistin and proinflammatory cyto-
kines, such as TNFα and IL-6. Markers of inflamma-
tion including CRP have been proposed for use in 
clinical practice to aid in the identification of asymp-
tomatic patients at high risk for CVD. Thus, meas-
urement of adiponectin and inflammatory markers 
could be used to assess the risk of developing CVD. 
It is important to note, however, that only a lim-
ited number of adipokines are released into the blood-
stream at levels that are detectable with current assays, 
resulting in increased circulating levels in the obese 
state. Some adipokines acting in a paracrine or 
autocrine manner may play an important role; thus, 
circulating levels of the adipokines may represent only 
spillover from WAT and may not be associated with 
the disease condition. Moreover, except for adi-
ponectin, many of the adipokines are not expressed 
exclusively in WAT. Thus, there remains uncertainty 
as to the most appropriate and optimal marker for use 
in clinical practice. Since various WAT in different 
regions may have unique characteristics related to 
differential expression of adipokines, different types of Int. J. Med. Sci. 2008, 5 
 
257
fat distribution may offer the explanations for the dis-
crepancies observed between different studies. Further 
epidemiological studies with solid clinical end points 
are needed to determine which combination of adi-
pokines can be a reliable risk marker for CVD and may 
provide an improved method for identifying persons 
at risk for future cardiovascular events. Elucidation of 
the significance of circulating adipokines may provide 
a therapeutic target for adipokine-based pharmacol-
ogical and/or interventional therapies in obesity and 
related complications. 
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